Rep. David Taylor Buys Medpace Holdings, Inc. (NASDAQ:MEDP) Stock

Representative David Taylor (R-Ohio) recently bought shares of Medpace Holdings, Inc. (NASDAQ:MEDP). In a filing disclosed on February 02nd, the Representative disclosed that they had bought between $1,001 and $15,000 in Medpace stock on January 29th. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.

Representative David Taylor also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Vertex Pharmaceuticals (NASDAQ:VRTX) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Salesforce (NYSE:CRM) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Installed Building Products (NYSE:IBP) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Prologis (NYSE:PLD) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 1/29/2026.

Medpace Price Performance

NASDAQ:MEDP opened at $568.53 on Wednesday. The firm has a market capitalization of $16.02 billion, a P/E ratio of 39.76, a PEG ratio of 1.98 and a beta of 1.42. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $628.92. The company’s 50-day simple moving average is $582.81 and its 200 day simple moving average is $536.08.

Analyst Ratings Changes

MEDP has been the topic of several analyst reports. Truist Financial set a $555.00 target price on Medpace in a report on Monday, October 27th. Barclays upped their price target on shares of Medpace from $485.00 to $525.00 and gave the stock an “underweight” rating in a research note on Monday, December 15th. Mizuho set a $660.00 price objective on shares of Medpace in a research note on Friday, January 9th. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a research note on Wednesday, January 28th. Finally, BMO Capital Markets assumed coverage on shares of Medpace in a report on Thursday, November 13th. They set a “market perform” rating and a $600.00 price target on the stock. Two equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $491.27.

Insider Activity at Medpace

In related news, CEO August J. Troendle sold 59,025 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $607.78, for a total value of $35,874,214.50. Following the transaction, the chief executive officer owned 774,602 shares of the company’s stock, valued at approximately $470,787,603.56. This trade represents a 7.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Susan E. Burwig sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the sale, the vice president owned 27,500 shares of the company’s stock, valued at $16,751,625. This trade represents a 42.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 320,192 shares of company stock worth $192,909,762 in the last quarter. Company insiders own 20.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Quent Capital LLC purchased a new stake in Medpace during the 3rd quarter valued at $25,000. Optiver Holding B.V. purchased a new stake in Medpace during the third quarter valued at $27,000. Geneos Wealth Management Inc. lifted its holdings in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the period. Steigerwald Gordon & Koch Inc. purchased a new position in Medpace in the fourth quarter worth about $30,000. Finally, Quarry LP bought a new stake in shares of Medpace during the 3rd quarter valued at about $35,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.